Advanced Biomed Inc.
ADVB
Analytical Summary
Advanced Biomed Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.
4-Year Financial Trajectory
AnnualBullish Indicators
- Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
Bearish Risks
- No bearish risks detected.
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2026 Jun 30, 2026 10-K ↗ | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) | N/M |
-14.3%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) | N/M |
-17.1%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-444.7%
Weak
Weak
Year-over-year change in free cash flow |
-159.3%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2026 Jun 30, 2026 10-K ↗ | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — | — |
| FCF / Net Income (x) |
-0.29x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.80x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.79x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2026 Jun 30, 2026 10-K ↗ | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-50.8%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — | — |
| Return on Capital (%) (%) |
-45.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — |
| Return on Common Equity (%) (%) |
54.4%
Excellent
↑
Excellent
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+263%)
|
-93.7%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-725%)
|
-167.3%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-1215%)
|
— |
| Metric | FY 2026 Jun 30, 2026 10-K ↗ | FY 2025 Jun 30, 2025 10-K ↗ | FY 2024 Jun 30, 2024 10-K ↗ | FY 2023 Jun 30, 2023 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $127.64K | — | — | — |
| Depreciation Expense (USD) | — | $224.83K | $268.28K | — |
| Net Income, GAAP (USD) | $6.68M | $-3.26M | $-2.78M | — |
| Operating Cash Flow (USD) | $-1.95M | $-5.83M | $-2.13M | — |
Secondary lens
Benchmark Lens
Compare ADVB against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ADVB against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for ADVB
Return on Common Equity (%) is in the top quartile
No bearish signals detected
Percentile Rankings
How ADVB compares to all companies
Compare ADVB with peers
Stack ADVB against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 4 days ago 4 years · 13 quarters